Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)
Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%
Castle Biosciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Castle Biosciences's price to sales ratio was 2.9× on Nov 11, 2026, against 3.4× a year earlier. Over the last 5 years it ranged from 1.3× to 12.7×, with a median of 2.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.9× | −0.4 |
| 2025 | Dec 31, 2025 | 3.3× | +0.9 |
| 2024 | Dec 31, 2024 | 2.4× | −0.6 |
| 2023 | Dec 29, 2023 | 3.0× | −2.0 |
| 2022 | Dec 30, 2022 | 5.0× | −7.5 |
| 2021 | Dec 31, 2021 | 12.6× | −8.6 |
| 2020 | Dec 31, 2020 | 21.2× | +8.3 |
| 2019 | Dec 31, 2019 | 12.9× | – |
See a number that looks wrong?